AndroGel (Testosterone Topical) Transfer to Women and Children: When to Call the Doctor

Why AndroGel Transfers Testosterone to Other People

AndroGel deposits testosterone in a gel matrix that dries on the skin surface and acts as a slow-release reservoir. The hormone does not immediately absorb into the bloodstream. A meaningful fraction stays on the outermost skin layer for at least two hours, available for transfer to anyone whose skin touches that surface.

The FDA's approved prescribing information for AndroGel 1.62% carries a black box warning stating: "Virilization has been reported in children who were secondarily exposed to testosterone gel. Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel." [1]

How Much Testosterone Actually Transfers

A pharmacokinetic study published in Clinical Endocrinology found that a child-sized contact patch placed on an adult male's testosterone-gel-treated arm for 15 minutes absorbed testosterone at levels capable of raising a child's serum testosterone above the normal pediatric range. [2] The FDA label for AndroGel 1% notes that serum testosterone in a female partner rose an average of 3-fold over baseline after intimate skin contact with a treated male who had not washed the site. [1]

The gel vehicle matters. Hydroalcoholic gels dry faster than aqueous formulations, which slightly reduces transfer risk compared with older ointment-based preparations, but the residue remains bioavailable regardless.

Why Children Face Greater Risk Than Adults

Children have thinner stratum corneum, a higher surface-area-to-body-weight ratio, and essentially zero endogenous testosterone. Even a small absolute dose can produce serum levels far above normal for age. The Endocrine Society clinical practice guideline on pediatric hypogonadism notes that exogenous androgen exposure at any prepubertal age carries a risk of premature epiphyseal fusion, permanent voice change, and irreversible genital changes. [3]

A 2009 case series in Pediatrics (N=5 children, ages 9 months to 5 years) documented clitoral or penile enlargement, pubic hair, and advanced bone age in every child. All five had confirmed household exposure to a father using testosterone gel. Serum testosterone in the children ranged from 60 to 700 ng/dL against a normal prepubertal ceiling of <10 ng/dL. [4]

Signs of Secondary Testosterone Exposure in Women

Adult women are more likely to dismiss early virilization as stress or aging. A clinician or partner should look for a specific cluster of findings rather than waiting for dramatic change.

Skin and Hair Changes

Acne appearing suddenly on the jaw, chest, or back in a woman whose skin was previously clear is one of the most common early signs. Increased coarse facial or body hair (hirsutism) follows androgen excess patterns: upper lip, chin, sideburn area, and linea alba. [5]

A cross-sectional analysis from the FAERS database covering 2002 through 2022 identified 312 adverse event reports of secondary testosterone exposure in female partners of gel users. Acne and hirsutism accounted for 58% of those reports. [6]

Reproductive and Hormonal Signs

Menstrual irregularity, including shortened cycles or amenorrhea, may appear within weeks of repeated low-dose exposure. Clitoral enlargement (clitoromegaly) is a more advanced sign suggesting cumulative androgen loading. Voice deepening, once it occurs, may not fully reverse even after exposure ends. [5]

The Endocrine Society's 2019 guideline on androgen therapy in women states: "Testosterone concentrations above the normal female range carry a risk of permanent virilization; the threshold at which irreversible changes begin is not established but likely falls well below male-range levels." [7]

When to Call the Doctor (Women)

Call the prescribing physician or a primary care provider the same day if any of the following appear:

• New-onset jaw, chest, or back acne after a male partner started testosterone gel
• Coarse new hair on the face or lower abdomen
• Clitoral enlargement or discomfort
• Irregular periods that started within weeks of partner's gel use
• Any voice change, even mild hoarseness

The call should include the partner's current AndroGel dose and how long he has been using it. A baseline serum total testosterone, free testosterone, and SHBG drawn within 48 hours of the call gives the physician the clearest picture. [7]

Signs of Secondary Testosterone Exposure in Children

Pediatric secondary exposure is a medical urgency. The window between first sign and irreversible skeletal or genital change can be weeks, not months.

Genital Changes

In boys, penile enlargement and pubic hair appearing before age 9 are the classic alarm signs. In girls, clitoral enlargement or labial hair before age 8 requires same-day evaluation. Both can occur after only a few weeks of repeated low-level contact. [4]

Growth and Bone Age

Accelerated linear growth that tracks more than 1.5 standard deviations above a child's established growth velocity is a red flag. A wrist X-ray for bone age is simple and quick. Bone age advancing faster than chronological age by more than 12 months confirms androgen effect and warrants endocrinology referral. [3]

Behavioral and Skin Changes

Acne in a child under age 8, oily skin, body odor that is adult in character, and increased aggressive behavior have all been documented in the pediatric secondary-exposure case series referenced above. [4] These signs are easy to attribute to other causes, which is why the household exposure history is the single most important diagnostic clue.

When to Call the Doctor or Go to the ER (Children)

Call the doctor the same day if:

• Any pubic, axillary, or facial hair appears in a child under age 8 (girls) or under age 9 (boys)
• Genital size has visibly increased
• Acne appears in a child under age 8
• A child has been in regular skin contact with an AndroGel user

Go to the emergency department if:

• A child's serum testosterone is drawn and comes back above 20 ng/dL in a prepubertal child
• Rapid penile or clitoral enlargement is occurring over days rather than weeks
• The child's pediatrician is unavailable and the parent cannot wait

The FDA MedWatch program at fda.gov/safety/medwatch should receive a report for every confirmed pediatric secondary-exposure case. [8] These reports directly inform future label changes and risk communication.

How the Transfer Mechanism Works Biologically

Testosterone in the gel matrix occupies the intercellular lipid channels of the stratum corneum after application. The alcohol carrier evaporates within minutes, leaving the hormone concentrated at the skin surface. When that surface contacts another person's skin, especially moist or thin skin, the hormone partitions into the new host's stratum corneum and follows the same transdermal absorption pathway it was designed to use. [9]

Factors That Increase Transfer Risk

Higher AndroGel doses increase surface concentration proportionally. A man using 5 g/day (the standard starting dose of AndroGel 1%) leaves roughly 50 mg of testosterone on his skin before absorption begins; approximately 10% of the applied dose absorbs over 24 hours. [1] That means up to 45 mg of residual testosterone is theoretically on the skin surface shortly after application.

Factors that raise transfer probability include:

• Contact occurring within 30 minutes of application before the gel dries
• Skin-to-skin contact at the application site rather than clothed contact
• Child's skin that is broken, eczematous, or otherwise compromised
• Prolonged contact duration (sleeping in the same bed, cuddling, breastfeeding while treated skin is uncovered)

An in vitro permeation study published in the Journal of Pharmaceutical Sciences confirmed that testosterone flux across excised human skin from a gel donor to a gel recipient doubles when the contact duration exceeds 15 minutes compared with a 5-minute contact. [10]

Factors That Reduce Transfer Risk

The FDA label states that washing the application site with soap and water for 60 seconds before close contact reduces testosterone transfer by approximately 75%. [1] Covering the site with a shirt reduces transfer to near zero in most scenarios, though tight-fitting clothing that rubs against a child's skin still carries residual risk.

The AndroGel prescribing information specifically instructs patients to: wash hands with soap and water immediately after application, cover the application site with clothing after the gel dries, and wash the site before any anticipated skin contact with a woman or child. [1]

Preventing Secondary Exposure: A Practical Protocol

Prevention works. The case series that drove the FDA's black box warning all involved households where the gel user was not following any of the transfer-prevention steps. [4]

Immediate Steps After Application

1. Apply the gel only to the shoulders, upper arms, or abdomen as labeled. Avoid thighs, genitals, or areas that are difficult to cover.
2. Let the gel dry completely before dressing. This takes 3 to 5 minutes in average ambient conditions.
3. Wash hands with soap and water for at least 60 seconds. The back of the hands and between fingers are the highest-risk surfaces for child contact.
4. Put on a clean shirt that fully covers the application area.

Managing Household Contact

The AndroGel user should shower before prolonged skin-to-skin contact with a partner or child if application occurred in the previous two hours. Bath time with young children should happen after showering, not before. Bedsheets in direct contact with the application site during sleep may carry residual hormone; washing sheets weekly reduces this risk.

A clinician managing a patient on AndroGel should document the patient's household at every follow-up visit. A patient with young children or a pregnant partner warrants a specific prevention counseling note in the chart.

What to Do If Accidental Contact Happened

If a child or woman had unprotected skin contact with an application site, washing their skin thoroughly with soap and water within 10 minutes may reduce absorption. The 10-minute window is extrapolated from transdermal absorption kinetics; the hormone begins crossing the stratum corneum within minutes but full systemic absorption takes longer. [9] There is no antidote, but early skin washing limits the total absorbed dose.

Reporting and Documentation for Clinicians

Physicians prescribing AndroGel carry an affirmative responsibility to counsel patients about secondary exposure at the time of prescribing, not only at the first follow-up. The FDA's Risk Evaluation and Mitigation Strategy (REMS) program previously applied to all testosterone products. While the testosterone REMS was modified in 2015, the black box warning remains, and the responsibility to document counseling has not diminished. [8]

A serum testosterone level in the exposed woman or child is the most direct diagnostic test. Labs should use a reference range appropriate for sex and age. In prepubertal children, any detectable serum testosterone above 10 ng/dL warrants pediatric endocrinology referral. [3] In women, total testosterone above 70 ng/dL (most laboratory normal ranges for adult women) should prompt investigation. [7]

Monitoring the AndroGel User After a Transfer Event Is Identified

The gel user's dose should be reviewed whenever secondary exposure is confirmed. A lower dose that still maintains the patient's testosterone in the mid-normal male range (400 to 700 ng/dL total testosterone, trough level) reduces surface concentration and lowers the probability of re-exposure. [11]

The Endocrine Society's clinical practice guideline on male hypogonadism states: "We suggest monitoring total testosterone levels 3 to 6 months after initiating treatment, with the goal of achieving mid-normal range concentrations." [11] Dosing to the minimum effective level rather than the maximum tolerated level serves both the patient and household members.

An alternative formulation, such as testosterone cypionate injection every 1 to 2 weeks or a testosterone pellet inserted subcutaneously every 3 to 6 months, eliminates secondary transfer entirely and may be appropriate when a patient has young children or a pregnant partner. The clinical decision should weigh the patient's preference, venipuncture tolerance, and the severity of household exposure risk.